Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer

Martina Kluth; Ramin Ahrary; Claudia Hube-Magg; Malik Ahmed; Heinke Volta; Catina Schwemin; Stefan Steurer; Corinna Wittmer; Waldemar Wilczak; Eike Burandt; Till Krech; Meike Adam; Uwe Michl; Hans Heinzer; Georg Salomon; Markus Graefen; Christina Koop; Sarah Minner; Ronald Simon; Guido Sauter; Thorsten Schlomm

doi:10.18632/oncotarget.14557

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer

Martina Kluth, Ramin Ahrary, Claudia Hube-Magg, Malik Ahmed, Heinke Volta, Catina Schwemin, Stefan Steurer, Corinna Wittmer, Waldemar Wilczak, Eike Burandt, Till Krech, Meike Adam, Uwe Michl, Hans Heinzer, Georg Salomon, Markus Graefen, Christina Koop, Sarah Minner, Ronald Simon _, Guido Sauter and Thorsten Schlomm

PDF | How to cite

Oncotarget. 2017; 8:3761-3761. https://doi.org/10.18632/oncotarget.14557

Metrics: PDF 2385 views | ?

Present: Due to a production error, proper equal contribution credit for the first and second authors was erroneously removed from the published version.

Corrected: The proper contributions are listed below. The publisher sincerely apologizes for this oversight.

Original article: Oncotarget. 2015; 6(29):27966-79. DOI: 10.18632/oncotarget.4626.

Martina Kluth^1,*, Ramin Ahrary^1,*, Claudia Hube-Magg¹, Malik Ahmed¹, Heinke Volta¹,Catina Schwemin¹, Stefan Steurer¹, Corinna Wittmer¹, Waldemar Wilczak¹, EikeBurandt¹, Till Krech¹, Meike Adam², Uwe Michl², Hans Heinzer², Georg Salomon², Markus Graefenv², Christina Koop¹, Sarah Minner¹, Ronald Simon¹, Guido Sauter¹,Thorsten Schlomm^2,3

¹ Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany
² Martini-Klinik, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
³ Dept. of Urology, Section for translational prostate cancer research, University Medical Center Hamburg-Eppendorf, Germany
^*These authors have contributted equally to this work

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14557

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer